0001209191-23-048453.txt : 20230906 0001209191-23-048453.hdr.sgml : 20230906 20230906172554 ACCESSION NUMBER: 0001209191-23-048453 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230901 FILED AS OF DATE: 20230906 DATE AS OF CHANGE: 20230906 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DeFord John A CENTRAL INDEX KEY: 0001403373 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-35621 FILM NUMBER: 231240221 MAIL ADDRESS: STREET 1: C R BARD INC STREET 2: 730 CENTRAL AVENUE CITY: MURRAY HILL STATE: NJ ZIP: 07974 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GLOBUS MEDICAL INC CENTRAL INDEX KEY: 0001237831 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 043744954 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2560 GENERAL ARMISTEAD AVENUE CITY: AUDUBON STATE: PA ZIP: 19403 BUSINESS PHONE: 610-930-1800 MAIL ADDRESS: STREET 1: 2560 GENERAL ARMISTEAD AVENUE CITY: AUDUBON STATE: PA ZIP: 19403 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0508 4/A 2023-09-01 2023-09-06 0 0001237831 GLOBUS MEDICAL INC GMED 0001403373 DeFord John A 2560 GENERAL ARMISTEAD AVE AUDUBON PA 19403 1 0 0 0 0 Class A Common Stock 2023-09-01 4 A 0 15578 A 15578 D Stock Option (Right to Buy Class A Common Stock) 54.23 2023-09-01 4 A 0 15000 0.00 A 2033-09-01 Class A Common Stock 15000 15000 D Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, NuVasive, Inc. ("NuVasive") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into NuVasive (the "Merger"), with NuVasive continuing as a wholly owned subsidiary of the Issuer. At the effective time of the Merger, each NuVasive restricted stock unit award was accelerated, cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Issuer, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of NuVasive common stock underlying such award. These options were granted on September 1, 2023, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on September 1, 2024, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months. The original Form 4, filed on September 6, 2023, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported an expiration date of September 1, 2024, when in fact such expiration date is September 1, 2033. /s/ Kelly G. Huller, Attorney-in-Fact 2023-09-06